See more : iTokk, Inc. (IKTO) Income Statement Analysis – Financial Results
Complete financial analysis of Beijing Succeeder Technology Inc. (688338.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beijing Succeeder Technology Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Sang-A Frontec Co.,Ltd. (089980.KQ) Income Statement Analysis – Financial Results
- Japan Pure Chemical Co., Ltd. (4973.T) Income Statement Analysis – Financial Results
- TaiSol Electronics Co., Ltd. (3338.TW) Income Statement Analysis – Financial Results
- CuraScientific Corp (CSTF) Income Statement Analysis – Financial Results
- Viridis Holdings Corp. (VRDSF) Income Statement Analysis – Financial Results
Beijing Succeeder Technology Inc. (688338.SS)
About Beijing Succeeder Technology Inc.
Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. Its products include coagulation analyzers and reagents, blood rheology analyzers, ESR analyzers, and platelet aggregation analyzers. The company was founded in 2003 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 275.49M | 228.81M | 239.92M | 222.40M | 229.57M | 200.09M | 156.70M | 125.37M |
| Cost of Revenue | 102.22M | 86.18M | 95.84M | 88.68M | 93.19M | 84.01M | 66.15M | 54.32M |
| Gross Profit | 173.27M | 142.64M | 144.08M | 133.72M | 136.38M | 116.08M | 90.55M | 71.05M |
| Gross Profit Ratio | 62.90% | 62.34% | 60.05% | 60.13% | 59.41% | 58.01% | 57.78% | 56.67% |
| Research & Development | 19.18M | 16.94M | 15.21M | 13.36M | 13.86M | 12.80M | 12.07M | 9.29M |
| General & Administrative | 3.00M | 2.77M | 3.32M | 3.86M | 3.07M | 3.31M | 11.09M | 6.58M |
| Selling & Marketing | 17.61M | 29.65M | 33.53M | 32.42M | 34.45M | 30.84M | 25.46M | 20.91M |
| SG&A | 20.43M | 32.41M | 36.85M | 36.28M | 37.52M | 34.15M | 36.55M | 27.49M |
| Other Expenses | -32.03M | 10.06M | 8.99M | 6.85M | 7.22M | 8.71K | -1.73M | 1.95M |
| Operating Expenses | 38.39M | 59.41M | 61.05M | 56.49M | 58.60M | 52.48M | 53.29M | 38.11M |
| Cost & Expenses | 140.61M | 145.59M | 156.89M | 145.16M | 151.79M | 136.49M | 119.44M | 92.43M |
| Interest Income | 30.70M | 28.39M | 28.36M | 13.13M | 4.05M | 1.42M | 644.82K | 0.00 |
| Interest Expense | 75.53K | 38.06K | 246.41K | 54.38K | 55.67K | 41.76K | 86.28K | 0.00 |
| Depreciation & Amortization | 4.96M | 6.97M | 8.14M | 4.48M | 3.20M | 1.68M | 1.57M | 2.38M |
| EBITDA | 140.99M | 126.98M | 120.70M | 81.67M | 84.94M | 65.58M | 39.59M | 35.32M |
| EBITDA Ratio | 51.18% | 55.59% | 50.81% | 36.92% | 35.58% | 33.18% | 25.59% | 28.28% |
| Operating Income | 134.88M | 117.88M | 108.28M | 84.81M | 81.72M | 65.46M | 36.67M | 33.73M |
| Operating Income Ratio | 48.96% | 51.52% | 45.13% | 38.14% | 35.60% | 32.71% | 23.40% | 26.91% |
| Total Other Income/Expenses | -19.24K | 2.00M | 3.99M | -4.97M | -32.27K | 8.72K | -1.73M | 1.95M |
| Income Before Tax | 134.86M | 119.88M | 112.26M | 79.84M | 81.69M | 65.46M | 34.94M | 35.68M |
| Income Before Tax Ratio | 48.95% | 52.39% | 46.79% | 35.90% | 35.58% | 32.72% | 22.30% | 28.46% |
| Income Tax Expense | 17.96M | 15.76M | 14.89M | 10.66M | 10.65M | 8.75M | 5.60M | 4.66M |
| Net Income | 116.91M | 104.11M | 97.37M | 69.19M | 71.04M | 56.71M | 29.35M | 31.02M |
| Net Income Ratio | 42.44% | 45.50% | 40.58% | 31.11% | 30.95% | 28.34% | 18.73% | 24.74% |
| EPS | 1.10 | 0.98 | 0.92 | 0.65 | 0.67 | 0.77 | 0.40 | 0.44 |
| EPS Diluted | 1.10 | 0.98 | 0.92 | 0.65 | 0.67 | 0.77 | 0.40 | 0.44 |
| Weighted Avg Shares Out | 106.28M | 106.14M | 106.14M | 106.14M | 106.14M | 73.73M | 73.37M | 70.75M |
| Weighted Avg Shares Out (Dil) | 106.14M | 106.14M | 106.14M | 106.14M | 106.14M | 73.73M | 73.37M | 70.75M |
Source: https://incomestatements.info
Category: Stock Reports